COVID-19 INFECTION IN RHEUMATIC IMMUNE-MEDIATED INFLAMMATORY DISEASES. EPIDEMIOLOGICAL STUDY IN A SINGLE UNIVERSITY HOSPITAL

D. Martínez-López1, D. Prieto-Peña1, L. Sanchez-Bilbao2, A. Herrera-Morant1, C. Álvarez-Reguera1, M. Trigueros-Vazquez1, M. A. Gonzalez-Gay1, R. Blanco1, Hospital Universitario Marqués de Valdecilla, Santander, Spain

Background: Immune-mediated inflammatory diseases (IMID) have an increased risk of infections due to the disease itself, and/or immunosuppressive therapy. Risk of COVID-19 infection in the different rheumatic IMID (R-IMID) remains controversial.

Objectives: To assess the epidemiology and comorbidities of COVID-19 in R-IMID from a Single-University hospital.

Methods: Cross-sectional study in a Single-University hospital. We included all consecutive patients with a diagnosis of a R-IMID and a positive test for COVID-19 up to November 6th, 2020. Medical records of 11,199 patients that suffered COVID-19 in our region, and 6891 with R-IMID from our hospital were reviewed. Incidence data in the different underlying R-IMID were calculated for patients with follow-up in our hospital. Confirmed infection was defined if the patient had a positive nasopharyngeal swab for SARS-CoV-2.

Results: We included 147 patients from our region (96 women/51 men), mean age 60±18 years. Underlying R-IMID were: Rheumatoid arthritis (RA) (n=36, 24.5%), Axial spondyloarthritis, Spondyloarthritis, SSc: Systemic scleroderma. GCA: Giant cell arteritis, PsA: Psoriatic arthritis, RA: Rheumatoid arthritis, SLE: Systemic lupus erythematosus, SpA: Axial spondyloarthritis, SSA: Systemic sclerosis.

In our series, the total cumulative incidence of COVID-19 in R-IMID was 1.7% (115/6891), ranging from 1.0% in Behçet’s disease to 2.2% in SpA/PsA.

Conclusion: In our series, the total cumulative incidence of COVID-19 in R-IMID was similar to the general population. Higher RR, without statistical significance, was observed in Behçet’s disease, ANCA-vasculitis and Polymyalgia Rheumatica.

Disclosure of Interests: None declared.

C. Álvarez-Reguera1, M. Trigueros-Vazquez1, M. A. González-Gay1, R. Blanco1, Hospital Universitario Marqués de Valdecilla, Santander, Spain

Background: Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) virus infection or COVID-19 is a serious problem for patients with systemic autoimmune diseases Given the serious complications, including acute lung injury, patients with systemic sclerosis (SSc), especially SSc associated with interstitial lung disease (ILD), may represent a high risk group for infection and the development of severe COVID-19.

Objectives: We present an analysis of the COVID-19 course and outcomes in 110 SSc pts.

Methods: The study included 147 patients with SSc. The information was clarified by means of phone survey after 10 months of the pandemic (December 2020). COVID-19 was diagnosed when confirmed by positive oral/nasopharyngeal swab, in the presence of positive antibodies and/or characteristic symptoms, and from chest computed tomography (CT). 110 pts (77%) out of 147 patients in the SSc registry, gave the necessary information. COVID-19 was diagnosed in 59 pts (53%), 42 pts (71%) had SSc-ILD. Pts mean age was 54.96 (s.d.11, min 31, max 79), 83% women (49 women and 10 men). 38 pts (65%) had a limited form of SSc, 15 (26%) pts had diffuse form SSc, 6% had overlap (SSc-polymyositis) and 3% had visceral form of SSc. All patients received low-dose prednisone, and more than half of the pts received immunosuppressive therapy. Rituximab therapy was performed in 54 pts (41%).

Results: Almost all patients had positive swab from the oral cavity/nasopharynx. And only in 4 (7%) pts nasopharyngeal swabs were negative, in these patients specific antibodies and characteristic CT changes were detected. Chest CT was performed in 51 (86%) pts. Novel coronavirus pneumonia developed in the vast majority of pts – in 46 (78%) pts, CT1 (up to 25% of lung lesions) had 10 (17%) pts, CT2 (25-50%) – 21 (36%) pts, CT3 (50-75%) – 15 (25%) pts. In 5 (8.5%) pts no changes were detected on CT. The course of COVID-19 was mild and moderate (20 (34%) pts and 18 (31%) pts respectively), severe course was observed in 21 (35%) pts, including fatal in 12 (20%) pts. Among the deceased pts, only 1 patient with SSc-PM had not had ILD, but 7 patients had been treated with rituximab.

Conclusion: SSc SARS-CoV-2-infected patients may be at risk of severe disease and mortality due to the frequent presence of ILD and the frequent use of immunosuppression, including biological therapy.

Disclosure of Interests: None declared.